57
The need to find improved vaccines for TB has become all the more pressing 58 following the discouraging results from human phase 2b trials of MVA85A(7-10), the most 59 advanced among the twelve candidate vaccines that are undergoing human clinical trials, 60 despite encouraging results in animal models. Development of effective TB vaccines is 61 constrained by lack of immune correlates of protection in humans and reliable animal models.
62
While interferon gamma (IFN-γ) was for long believed to be a correlate of protective immune 63 responses against MTB based primarily on the increased susceptibility to TB of mice lacking Figure 1B corroborating the neutrophil-dependent inflammatory signature reported in TB patients (50).
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As a comparison, we also carried out PFT analysis in our cohort in response to the 
